SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as investors are digesting news of a significant AI hosting agreement with Fluidstack, which includes backing from Google; the community is weighing the long-term potential against concerns about near-term dilution from a proposed convertible note offering. Discussions revolve around the company's strategic shift from Bitcoin mining to AI data centers and the implications of Google's involvement and potential for future deals. Some traders point out the growth potential of the sector while others express concerns about near-term price action.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending amid discussions around its high valuation compared to competitors like CarMax, with community members pointing to insider selling and subprime lending practices. Some traders are anticipating a continued pump, while others believe the stock is overvalued and due for a correction, especially in light of CarMax's recent performance and concerns about Carvana's loan portfolio. The stock's unusual price action and the potential impact of future interest rate decisions are also being closely monitored.

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

PepGen Inc

PepGen is trending due to discussions around a recent public offering of shares, alongside positive clinical trial results for their DM1 drug which showed a significant splicing correction. The community is debating the impact of the dilution from the offering versus the potential of the clinical data and analyst upgrades. Short squeeze potential is also being discussed.

China Natural Resources, Inc. is an investment holding company. The firm is primarily involved in the exploration and mining in the People’s Republic of China (PRC). It is engaged in the exploration for lead, silver, and other metals, and copper trading in the Inner Mongolia Autonomous Region of the PRC. The company was founded on December 14, 1993 and is headquartered in Hong Kong.

China Natural Resources Inc

China Natural Resources is trending due to its pursuit of a lithium mine acquisition in Zimbabwe, sparking excitement among investors. The community is discussing the stock's low float and potential for a significant run, drawing parallels to other lithium plays. Zero borrow availability is also adding to the bullish sentiment.

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

SciSparc Ltd

Scisparc Ltd

SPRC is trending due to news regarding a court stay on its merger with AutoMax Motors, extending the deadline to September 2025, which is causing volatility as the community debates the potential outcomes. The stock's low float and high short interest are also contributing to the intense trading activity, with some traders anticipating a short squeeze. SPRC's association with both the automotive sector and biotech (quantum computing initiative) adds to the speculative interest.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors digest news of a settlement with the FTC regarding Prime subscriptions, with the community debating its impact. Bullish sentiment is fueled by an upgrade from Wells Fargo citing strong AWS growth potential and AI investments. Some traders anticipate catalysts related to upcoming events and potential breakouts, while others remain skeptical, pointing to recent underperformance.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to a claimed breakthrough in converting photons to telecom wavelengths, seen as a critical step for quantum networking and a potential leap toward a quantum internet. Community members are debating the stock's valuation and short squeeze potential, while some point to insider selling and broader market concerns. Discussions also involve the company's competitive positioning and potential government contracts.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the implications of ongoing legal battles and potential legislative solutions regarding reimbursement for Xphozah, while also weighing positive sales momentum for Ibsrela. Community members are actively discussing upcoming conferences, recent insider trading activity, and debating the stock's potential trajectory amidst low trading volume. Some are expressing optimism about positive prescription data, potential partnership deals and the possibility of a positive court outcome.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as the stock price fluctuates, impacted by Bitcoin's movements and potential dilution concerns. The community is actively discussing technical levels, potential short squeezes, and the overall correlation between the stock and Bitcoin. Some traders express frustration with the stock's performance, while others see it as a leveraged play on Bitcoin's future.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors react to broader sector news, including potential government initiatives to support rare earth mining and processing, as well as rising rare earth prices. The community is discussing the company's strategic importance in the U.S. supply chain and its potential for further growth, as well as the potential impact of developments with other companies in the sector. Discussions also include the stock's technical indicators and potential price movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of PepGen (PEPG) more than doubled on Thursday morning after multiple analysts raised their price targets on the stock following the release of positive clinical data from an early-stage study in patients with myotonic dystrophy type 1.Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.Myotonic dystrophy type 1 (DM1) is a progressive disorder that primarily affects skeletal, cardiac, and smooth muscle. It is estimated to affect about 40,000 patients in the U.S.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.pepgen.com/news-releases/news-release-details/pepgen-announces-highest-mean-splicing-correction-reported-dm1">announced</a> on Wednesday that a 53.7% mean splicing correction was observed in DM1 patients following a single 15 mg/kg dose of its PGN-EDODM1, which is higher than any previously reported splicing correction in DM1 patients. All patients who received the dose in the trial showed an improvement in splicing correction, the company noted.“Since mis-splicing is the underlying cause of DM1, we believe high levels of splicing correction have the potential to reverse the underlying molecular defects, and produce functional improvements in multiple outcome measures, including myotonia and muscle weakness, in repeat dose studies,” said Paul Streck, Executive Vice President of Research and Development at PepGen.The company previously reported mean splicing correction of 12.3% and 29.1%, respectively, with 5mg/kg and 10mg/kg doses of PGN-EDODM1.The investigational candidate was well-tolerated at a dose of 15 mg/kg, and no serious treatment-related adverse events were identified, the company stated. However, one patient had to receive oral antihistamines for treatment-related adverse events, it said.PepGen's nearly 54% correction sets a new benchmark and "strongly suggests that repeat dosing could yield clinically meaningful functional benefit," contends H.C. Wainwright.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PEPG">PEPG stock </a>rose from 'neutral' to 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'extremely high' levels.&nbsp;PEPG stock is up 51% this year but down approximately 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/carmax-stock-tumbles-after-q2-earnings/chDlO6OR348">Why Did CarMax Stock Tumble 24% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

PepGen Stock More Than Doubles On Thursday – Check Out The New Price Targets On Wall Street

Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.

Equity

Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.


AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

PepGen Inc. (PEPG) shares are on track for their best weekly performance since September 2022, surging 77% as retail interest skyrockets.&nbsp;The stock saw a 150% weekly spike in followers on Stocktwits, making it the fastest-growing biotech stock by retail engagement in this period.The rally follows PepGen's release of early clinical data from its FREEDOM-DM1 Phase 1 trial, evaluating PGN-EDODM1 in myotonic dystrophy type 1 (DM1) – a genetic disorder that causes progressive muscle weakness and wasting.The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing. While single-dose studies haven't shown functional improvements, PepGen sees early trends suggesting potential benefits with repeat dosing.The biotech firm expects results from the 15 mg/kg cohort in the second half of 2025 and from the FREEDOM2 5 mg/kg cohort in Q1 2026.H.C. Wainwright called the data "very encouraging," highlighting that the 29.1% splicing correction could have therapeutic significance, as all individuals in the study showed over 10% change in the splicing index.The research firm has a 'Buy' rating and a $16 price target.Stifel also noted a "highly promising signal on splicing" and saw an improved probability of success for PGN-EDODM1. The analyst called the results a "clear win" against low expectations, especially with PepGen trading below cash.On the financial side, PepGen reported a fourth-quarter loss of $0.68, better than an anticipated $0.72 loss. The company ended 2024 with $120.2 million in cash and equivalents, which it expects to fund operations into 2026.Some traders see PepGen as undervalued after its recent pullback, pointing to solid DM1 data and nearly $4 per share in cash.&nbsp;<stembedurl>https://stocktwits.com/BiotechValues/message/606027696</stembedurl>Another investor highlighted its strong cash position, no immediate financing risk, and promising trial results, arguing the selloff mid-week has made the stock's risk-reward profile more attractive.<stembedurl>https://stocktwits.com/BluntForceOptions/message/605835158</stembedurl>Short interest on <a href="https://stocktwits.com/symbol/PEPG">PepGen's stock</a> has edged down from 2.5% at the start of the year to 2.1% at the end of last week, according to Koyfin data.Shares of the company are down more than 84% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Short interest on PepGen's stock has edged down from 2.5% at the start of the year to 2.1% at the end of last week, according to Koyfin data. | Image source: Getty Images

PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz?

The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder.

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and...

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG...

PepGen Announces CONNECT Program Updates

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc...

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Stocktwits

Costco Wholesale Corp

) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

PEPG
PepGen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PEPG News

PEPG PepGen Inc